{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:47:01Z","timestamp":1773661621873,"version":"3.50.1"},"reference-count":27,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively. Both RA and D3 decreased the expression of PDGFR-\u03b1 and PDGFR-\u03b2 throughout differentiation. When cells were treated with the PDGFR inhibitor AG1296 in addition to RA or D3, signs of terminal differentiation such as inducible oxidative metabolism and cell substrate adhesion were enhanced. These changes were accompanied by an increased extracellular signal-regulated kinase 1\/2 activation. AG1296 also resulted in elevated expression of differentiation markers CD11b and CD66c when administered with RA or D3. Interestingly, other markers did not follow the same pattern. Cells receiving AG1296 in addition to RA or D3 showed decreased G1-G0 arrest and CD14, CD38, and CD89 expression. We thus provide evidence that certain sets of differentiation markers can be enhanced, whereas others can be inhibited by the PDGFR pathway. In addition, we found calcium levels to be decreased by RA and D3 but increased when AG1296 was given in addition to RA or D3, suggesting that calcium levels decrease during myeloid or monocytic differentiation, and elevated calcium levels can disturb the expression of certain differentiation markers. [Cancer Res 2007;67(16):7765\u201371]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-0014","type":"journal-article","created":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T19:18:10Z","timestamp":1187205490000},"page":"7765-7772","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Platelet-Derived Growth Factor Receptor Regulates Myeloid and Monocytic Differentiation of HL-60 Cells"],"prefix":"10.1158","volume":"67","author":[{"given":"Gudrun","family":"Reiterer","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cornell University, Ithaca, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cornell University, Ithaca, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,15]]},"reference":[{"key":"2022061623340417000_B1","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med\u20082003; 348: 1201\u201314.","DOI":"10.1056\/NEJMoa025217"},{"key":"2022061623340417000_B2","doi-asserted-by":"crossref","unstructured":"Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell\u20081994; 77: 307\u201316.","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"2022061623340417000_B3","doi-asserted-by":"crossref","unstructured":"Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor \u03b2 receptor in chronic myelomonocytic leukemia. Blood\u20082001; 98: 2518\u201325.","DOI":"10.1182\/blood.V98.8.2518"},{"key":"2022061623340417000_B4","doi-asserted-by":"crossref","unstructured":"Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res\u20082001; 80: 1\u201338.","DOI":"10.1016\/S0065-230X(01)80010-5"},{"key":"2022061623340417000_B5","doi-asserted-by":"crossref","unstructured":"Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor \u03b2. N Engl J Med\u20082002; 347: 48\u20137.","DOI":"10.1056\/NEJMoa020150"},{"key":"2022061623340417000_B6","doi-asserted-by":"crossref","unstructured":"Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer\u20082002; 100: 623\u20136.","DOI":"10.1002\/ijc.10535"},{"key":"2022061623340417000_B7","doi-asserted-by":"crossref","unstructured":"Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell\u20082003; 3: 439\u201343.","DOI":"10.1016\/S1535-6108(03)00089-8"},{"key":"2022061623340417000_B8","doi-asserted-by":"crossref","unstructured":"Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. BioEssays\u20082001; 23: 494\u2013507.","DOI":"10.1002\/bies.1069"},{"key":"2022061623340417000_B9","unstructured":"Dubois-Dalcq M, Murray K. Why are growth factors important in oligodendrocyte physiology? Pathol Biol (Paris)\u20082000; 48: 80\u20136."},{"key":"2022061623340417000_B10","doi-asserted-by":"crossref","unstructured":"Artemenko Y, Gagnon A, Aubin D, Sorisky A. Anti-adipogenic effect of PDGF is reversed by PKC inhibition. J Cell Physiol\u20082005; 204: 646\u201353.","DOI":"10.1002\/jcp.20314"},{"key":"2022061623340417000_B11","doi-asserted-by":"crossref","unstructured":"Tamama K, Fan VH, Griffith LG, Blair HC, Wells A. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells\u20082006; 24: 686\u201395.","DOI":"10.1634\/stemcells.2005-0176"},{"key":"2022061623340417000_B12","doi-asserted-by":"crossref","unstructured":"Li K, Li CK, Chuen CK, et al. Preclinical ex vivo expansion of G-CSF\u2013mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy. Eur J Haematol\u20082005; 74: 128\u201335.","DOI":"10.1111\/j.1600-0609.2004.00343.x"},{"key":"2022061623340417000_B13","doi-asserted-by":"crossref","unstructured":"Yoshida H, Takakura N, Hirashima M, et al. Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Dev Comp Immunol\u20081998; 22: 321\u201332.","DOI":"10.1016\/S0145-305X(98)00008-1"},{"key":"2022061623340417000_B14","doi-asserted-by":"crossref","unstructured":"Tsiftsoglou AS, Pappas IS, Vizirianakis IS. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther\u20082003; 100: 257\u201390.","DOI":"10.1016\/j.pharmthera.2003.09.002"},{"key":"2022061623340417000_B15","unstructured":"Yen A, Forbes M, DeGala G, Fishbaugh J. Control of HL-60 cell differentiation lineage specificity, a late event occurring after precommitment. Cancer Res\u20081987; 47: 129\u201334."},{"key":"2022061623340417000_B16","doi-asserted-by":"crossref","unstructured":"Yen A, Brown D, Fishbaugh J. Control of HL-60 monocytic differentiation. Different pathways and uncoupled expression of differentiation markers. Exp Cell Res\u20081987; 168: 247\u201354.","DOI":"10.1016\/0014-4827(87)90432-0"},{"key":"2022061623340417000_B17","doi-asserted-by":"crossref","unstructured":"Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev\u20082004; 15: 229\u201335.","DOI":"10.1016\/j.cytogfr.2004.03.010"},{"key":"2022061623340417000_B18","doi-asserted-by":"crossref","unstructured":"Di Noto R, Lo Pardo C, Schiavone EM, et al. All\u2013trans-retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma\u20081996; 21: 201\u20139.","DOI":"10.3109\/10428199209067601"},{"key":"2022061623340417000_B19","doi-asserted-by":"crossref","unstructured":"Sun L, Iqbal J, Zaidi S, et al. Structure and functional regulation of the CD38 promoter. Biochem Biophys Res Commun\u20082006; 341: 804\u20139.","DOI":"10.1016\/j.bbrc.2006.01.033"},{"key":"2022061623340417000_B20","doi-asserted-by":"crossref","unstructured":"Barata H, Thompson M, Zielinska W, et al. The role of cyclic-ADP-ribose-signaling pathway in oxytocin-induced Ca2+ transients in human myometrium cells. Endocrinology\u20082004; 145: 881\u20139.","DOI":"10.1210\/en.2003-0774"},{"key":"2022061623340417000_B21","doi-asserted-by":"crossref","unstructured":"Woollard KJ, Fisch C, Newby R, Griffiths HR. C-reactive protein mediates CD11b expression in monocytes through the non-receptor tyrosine kinase, Syk, and calcium mobilization but not through cytosolic peroxides. Inflamm Res\u20082005; 54: 485\u201392.","DOI":"10.1007\/s00011-005-1382-5"},{"key":"2022061623340417000_B22","doi-asserted-by":"crossref","unstructured":"Kawagoe H, Grosveld GC. MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. Blood\u20082005; 106: 4278\u201386.","DOI":"10.1182\/blood-2005-04-1674"},{"key":"2022061623340417000_B23","doi-asserted-by":"crossref","unstructured":"Miyake S, Lupher ML, Jr., Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor \u03b1. Proc Natl Acad Sci U S A\u20081998; 95: 7927\u201332.","DOI":"10.1073\/pnas.95.14.7927"},{"key":"2022061623340417000_B24","doi-asserted-by":"crossref","unstructured":"McCarthy TV, Datar S, Mackrill JJ. Activation of ryanodine receptor\/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma. FEBS Lett\u20082003; 554: 133\u20137.","DOI":"10.1016\/S0014-5793(03)01122-0"},{"key":"2022061623340417000_B25","doi-asserted-by":"crossref","unstructured":"Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs EG, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci\u20081995; 766: 416\u201330.","DOI":"10.1111\/j.1749-6632.1995.tb26691.x"},{"key":"2022061623340417000_B26","doi-asserted-by":"crossref","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia\u20082004; 18: 189\u2013218.","DOI":"10.1038\/sj.leu.2403241"},{"key":"2022061623340417000_B27","doi-asserted-by":"crossref","unstructured":"Lee-Chiong T, Jr., Matthay RA. Drug-induced pulmonary edema and acute respiratory distress syndrome. Clin Chest Med\u20082004; 25: 95\u2013104.","DOI":"10.1016\/S0272-5231(03)00128-X"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/16\/7765\/2571553\/7765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/16\/7765\/2571553\/7765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:46:43Z","timestamp":1655437603000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/16\/7765\/533308\/Platelet-Derived-Growth-Factor-Receptor-Regulates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":27,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2007,8,15]]},"published-print":{"date-parts":[[2007,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-0014","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}